LC-MF-4

LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research[1]. Pink: FGFR3 ligand (HY-175414) ; Blue: VHL ligase ligand (HY-125905) ; Black: linker (HY-Y1224)

Product Specifications

UNSPSC

12352005

Target

ATP Synthase; FGFR; PROTACs

Related Pathways

Membrane Transporter/Ion Channel; PROTAC; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

COC1=CC(OC)=C(C(NC(N(C2=NC=NC(CC3=CC=C(C=C3)N4CCN(CC4)CCCCCOC5=CC(C6=C(N=CS6)C)=CC=C5CNC([C@@H]7C[C@H](CN7C([C@H](C(C)(C)C)NC(C8(CC8)F)=O)=O)O)=O)=C2)C)=O)=C1Cl)Cl

Molecular Formula

C56H69Cl2FN10O8S

Molecular Weight

1132.18

References & Citations

[1]Zheng L, et al. LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered Cancers. J Med Chem. 2025 Jul 10;68 (13) :13858-13871.